# SAB Biotherapeutics, Inc.: Form 8-K, filed Jan 3, 2024

- Company: [SAB Biotherapeutics, Inc.](/companies/sabs.md) (CIK 1833214)
- Form: 8-K
- Filed: 2024-01-03
- Accepted by EDGAR: Jan 3, 2024, 09:00 ET
- Period: 2024-01-02
- Accession: 0000950170-24-000543
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024000543/sabs-20240102.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1833214/000095017024000543/

## Items reported

- Item 3.03: Change to security holders’ rights
- Item 5.03: Amendment to articles or bylaws
- Item 5.07: Shareholder vote results
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1833214/000095017024000543/sabs-20240102.htm

Filed Jan 3, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-000543. Last ingested by Listed: Nov 5, 2026, 12:06 ET. No prices; not investment advice.